<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00090233</url>
  </required_header>
  <id_info>
    <org_study_id>V260-006</org_study_id>
    <secondary_id>2004_012</secondary_id>
    <nct_id>NCT00090233</nct_id>
  </id_info>
  <brief_title>Rotavirus Efficacy and Safety Trial (REST)(V260-006)</brief_title>
  <official_title>Safety and Efficacy of Pentavalent (G1, G2, G3, G4 , and P1) Human-Bovine Reassortant Rotavirus Vaccine in Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the safety of the investigational rotavirus vaccine and
      the efficacy to prevent rotavirus gastroenteritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intussusception Within 42 Days Following Any Dose of RotaTeq™/Placebo</measure>
    <time_frame>Within 42 days following any dose of RotaTeq™/placebo</time_frame>
    <description>Number of participants with confirmed intussusception within 42 days after each vaccination with RotaTeq™/placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Rotavirus Disease Caused by Serotypes G1, G2, G3 and G4 That Occurs 14 Days Following the 3rd Vaccination</measure>
    <time_frame>At least 14 days following the 3rd vaccination through the first full rotavirus season</time_frame>
    <description>Rotavirus gastroenteritis cases consist of all participants with one or more episodes classified as positive. Multiple positive episodes for one participant are counted as a single case.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>G1 Serum Neutralizing Antibody (SNA) Responses Against Rotavirus</measure>
    <time_frame>14 days following the 3rd vaccination</time_frame>
    <description>Number of participants with a 3-fold rise or greater in G1 Serum neutralizing antibody (SNA) responses against rotavirus from baseline to postdose 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Hospital Admissions and Visits to Emergency Departments (or the Equivalent at International Sites) for Rotavirus Disease Associated With Serotypes G1, G2, G3, or G4</measure>
    <time_frame>At least 14 days following the 3rd vaccination</time_frame>
    <description>Health Outcomes Substudy - Occurrence of hospital admissions and emergency department visits for episode(s) of rotavirus gastroenteritis associated with serotypes G1, G2, G3, or G4 by treatment group. Occurrence was expressed as the annual number of events per 1000 person-years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of a 3-dose Regimen of RotaTeq™ Against Moderate-to-severe Rotavirus Disease (Clinical Score &gt;8) Caused by Serotypes G1, G2, G3, and G4 Occurring at Least 14 Days Following the Third Dose.</measure>
    <time_frame>At least 14 days following the 3rd vaccination through the first rotavirus season</time_frame>
    <description>Number of participants with rotavirus gastroenteritis whose clinical score was &gt;8 for the first episode and for the worst episode. Scores evaluated the intensity and duration of diarrhea, vomiting, fever, and behavioral symptoms. The total score for an episode is equal to the sum of the scores for each of the symptoms [range: total score 0 (best) to 24 (worst)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of a 3-dose Regimen of RotaTeq™ Against Severe Rotavirus Disease (Clinical Score &gt; 16) Caused by Serotypes G1, G2, G3, and G4 Occurring at Least 14 Days Following the Third Dose</measure>
    <time_frame>At least 14 days following the 3rd vaccination through the first rotavirus season</time_frame>
    <description>Number of participants with rotavirus gastroenteritis whose clinical score was &gt;16 for the first episode and for the worst episode. Scores evaluated the intensity and duration of diarrhea, vomiting, fever, and behavioral symptoms. The total score for an episode is equal to the sum of the scores for each of the symptoms [range: total score 0 (best) to 24 (worst)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection/Seroconversion for Hepatitis B, Haemophilus Influenzae Type b, Diphtheria, Tetanus, &amp; Polio Types 1,2,&amp; 3 Who Received COMVAX™, INFANRIX™, IPOL™ &amp; PREVNAR™ Concomitantly With RotaTeq™ Versus Placebo</measure>
    <time_frame>42 days following third dose</time_frame>
    <description>The number of participants who achieved seroprotection/seroconversion to hepatitis B, Haemophilus influenzae type b, diphtheria, tetanus, &amp; polio types 1, 2, &amp; 3, per established criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Titer(s) (GMT) to Pertussis Toxin (PT), Pertussis Filamentous Haemagglutinin (FHA), and Pertussis Pertactin</measure>
    <time_frame>42 days following third dose</time_frame>
    <description>Measurement of immune response in the group that received RotaTeq™ and the group that received placebo was performed by determining geometric mean antibody titers to Pertussis Toxin (PT), Pertussis Filamentous Haemagglutinin (FHA), and Pertussis Pertactin. Antibody titers were measured with an indirect, non-competitive, enzyme immunoassay (EIA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Titer(s) (GMT) to Pneumococcal Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F</measure>
    <time_frame>42 days following third dose</time_frame>
    <description>Measurement of immune response in the group that received RotaTeq™ and the group that received placebo was performed by determining geometric mean antibody titers to pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. Serum antibody titers to type-specific pneumococcal polysaccharides were determined by an EIA.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69274</enrollment>
  <condition>Rotavirus Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RotaTeq</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotateq™</intervention_name>
    <description>3 doses of 2.0 mL RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>V260</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>3 doses of 2.0 mL Placebo to RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy infants

        Exclusion Criteria:

          -  None Specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM; Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006 Jan 5;354(1):23-33.</citation>
    <PMID>16394299</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2004</study_first_submitted>
  <study_first_submitted_qc>August 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2004</study_first_posted>
  <results_first_submitted>June 29, 2009</results_first_submitted>
  <results_first_submitted_qc>April 6, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2011</results_first_posted>
  <last_update_submitted>September 18, 2015</last_update_submitted>
  <last_update_submitted_qc>September 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotavirus Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at 356 sites in Belgium, Costa Rica, Finland, Germany, Guatemala, Italy, Jamaica, Mexico, Puerto Rico, Sweden, Taiwan, and the United States from 12 Jan 2001 first patient in (FPI) to 06 Oct 2004 last patient in (LPI).</recruitment_details>
      <pre_assignment_details>Participants with: history of congenital abdominal disorders, intussusception, or abdominal surgery; history of
known prior rotavirus disease, chronic diarrhea, or failure to thrive were excluded from the trial before
assignment to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RotaTeq™</title>
          <description>Three oral doses (~6.5x10^7 to ~1.2x10^8 IU/dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow-up after each vaccination, and follow-up for acute gastrointestinal episodes (AGEs) through the first rotavirus season postvaccination. The rotavirus season for each site was prospectively determined using historical epidemiologic data.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow-up after each vaccination, and follow-up for acute gastrointestinal episodes (AGEs) through the first rotavirus season postvaccination. The rotavirus season for each site was prospectively determined using historical epidemiologic data.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34644">Evaluated by data safety monitoring board (DSMB) when they recommended stopping enrollment</participants>
                <participants group_id="P2" count="34630">Evaluated by data safety monitoring board when they recommended stopping enrollment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Visit 1</title>
              <participants_list>
                <participants group_id="P1" count="34035">Randomized Not vaccinated 609</participants>
                <participants group_id="P2" count="34003">Randomized Not vaccinated 627</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Visit 2</title>
              <participants_list>
                <participants group_id="P1" count="31052"/>
                <participants group_id="P2" count="31066"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Visit 3</title>
              <participants_list>
                <participants group_id="P1" count="29667"/>
                <participants group_id="P2" count="29598"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29645">Does not include participants who discontinued prior to the 42 day safety follow-up</participants>
                <participants group_id="P2" count="29565">Does not include participants who discontinued prior to the 42 day safety follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4999"/>
                <participants group_id="P2" count="5065"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized Not Vaccinated (Visit 1)</title>
              <participants_list>
                <participants group_id="P1" count="609"/>
                <participants group_id="P2" count="627"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
                <participants group_id="P2" count="198"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="960"/>
                <participants group_id="P2" count="1022"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="211"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="189"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1211"/>
                <participants group_id="P2" count="1160"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Data not available at data cut-off point</title>
              <participants_list>
                <participants group_id="P1" count="1552"/>
                <participants group_id="P2" count="1563"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RotaTeq™</title>
          <description>Three oral doses (~6.5x10^7 to ~1.2x10^8 IU/dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34644"/>
            <count group_id="B2" value="34630"/>
            <count group_id="B3" value="69274"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>The eligibility for this study was to enroll infants 6-12 weeks of age; however infants that were 5 weeks and under, and infants who were 12 weeks and over were inadvertently enrolled outside these ranges. Those infants who received at least 1 dose of study vaccine, were followed for safety.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>5 Weeks of Age and Under</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 12 Weeks of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34551"/>
                    <measurement group_id="B2" value="34527"/>
                    <measurement group_id="B3" value="69078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Over 12 Weeks of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17058"/>
                    <measurement group_id="B2" value="17101"/>
                    <measurement group_id="B3" value="34159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17586"/>
                    <measurement group_id="B2" value="17529"/>
                    <measurement group_id="B3" value="35115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23772"/>
                    <measurement group_id="B2" value="23788"/>
                    <measurement group_id="B3" value="47560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4963"/>
                    <measurement group_id="B2" value="4911"/>
                    <measurement group_id="B3" value="9874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2908"/>
                    <measurement group_id="B2" value="2941"/>
                    <measurement group_id="B3" value="5849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi Racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1815"/>
                    <measurement group_id="B2" value="1817"/>
                    <measurement group_id="B3" value="3632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="536"/>
                    <measurement group_id="B2" value="552"/>
                    <measurement group_id="B3" value="1088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="531"/>
                    <measurement group_id="B2" value="514"/>
                    <measurement group_id="B3" value="1045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intussusception Within 42 Days Following Any Dose of RotaTeq™/Placebo</title>
        <description>Number of participants with confirmed intussusception within 42 days after each vaccination with RotaTeq™/placebo.</description>
        <time_frame>Within 42 days following any dose of RotaTeq™/placebo</time_frame>
        <population>All participants in the study were followed for potential cases of intussusception.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>Three oral doses (~6.5x10^7 to ~1.2x10^8 IU/dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Intussusception Within 42 Days Following Any Dose of RotaTeq™/Placebo</title>
          <description>Number of participants with confirmed intussusception within 42 days after each vaccination with RotaTeq™/placebo.</description>
          <population>All participants in the study were followed for potential cases of intussusception.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34002"/>
                <count group_id="O2" value="33969"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative Risk ≤10.0 (non-inferiority margin).</non_inferiority_desc>
            <p_value>0.006</p_value>
            <p_value_desc>p≤ 10/11, where p is proportion of participants with intussusception in vaccine group relative to total number of participants with intussusception. Based on conditional binomial approach.
Adjusted for group-sequential design.</p_value_desc>
            <method>Exact binomial test</method>
            <method_desc>Exact binomial test adjusted for group-sequential design.</method_desc>
            <param_type>relative risk</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>6.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>G1 Serum Neutralizing Antibody (SNA) Responses Against Rotavirus</title>
        <description>Number of participants with a 3-fold rise or greater in G1 Serum neutralizing antibody (SNA) responses against rotavirus from baseline to postdose 3.</description>
        <time_frame>14 days following the 3rd vaccination</time_frame>
        <population>Per Protocol Population among participants in Finland using Per-Protocol Case Definition</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>Participants randomized to treatment with RotaTeq™ tested with data available for analysis excluding protocol violators, participants with invalid data based on laboratory determinations, participants with wildtype rotavirus detected in the stool, or with samples taken outside the range of 9 to 33 days postdose 3.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomized to treatment with Placebo tested with data available for analysis excluding protocol violators, participants with invalid data based on laboratory determinations, participants with wildtype rotavirus detected in the stool, or with samples taken outside the range of 9 to 33 days postdose 3.</description>
          </group>
        </group_list>
        <measure>
          <title>G1 Serum Neutralizing Antibody (SNA) Responses Against Rotavirus</title>
          <description>Number of participants with a 3-fold rise or greater in G1 Serum neutralizing antibody (SNA) responses against rotavirus from baseline to postdose 3.</description>
          <population>Per Protocol Population among participants in Finland using Per-Protocol Case Definition</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p≥42%, where p is proportion of participants with ≥3-fold rise in antibody titer from Predose 1 to Postdose 3 in vaccine group. Based on binomial approach.</p_value_desc>
            <method>Exact binomial test</method>
            <param_type>Proportion</param_type>
            <param_value>81.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>72.9</ci_lower_limit>
            <ci_upper_limit>87.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Rotavirus Disease Caused by Serotypes G1, G2, G3 and G4 That Occurs 14 Days Following the 3rd Vaccination</title>
        <description>Rotavirus gastroenteritis cases consist of all participants with one or more episodes classified as positive. Multiple positive episodes for one participant are counted as a single case.</description>
        <time_frame>At least 14 days following the 3rd vaccination through the first full rotavirus season</time_frame>
        <population>Per Protocol Population Using Per-Protocol Case Definition</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>The number of participants randomized to treatment with RotaTeq™ is different from the number analyzed because some participants were excluded due to protocol violations and/or participants without follow-up and/or participants classified as unevaluable due to detection of wildtype rotavirus in the stool prior to 14 days Postdose 3; incomplete clinical and/or laboratory results; or stool samples collected out of day range.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The number of participants randomized to treatment with Placebo is different from the number analyzed because some participants were excluded due to protocol violations and/or participants without follow-up and/or participants classified as unevaluable due to detection of wildtype rotavirus in the stool prior to 14 days Postdose 3; incomplete clinical and/or laboratory results; or stool samples collected out of day range.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Rotavirus Disease Caused by Serotypes G1, G2, G3 and G4 That Occurs 14 Days Following the 3rd Vaccination</title>
          <description>Rotavirus gastroenteritis cases consist of all participants with one or more episodes classified as positive. Multiple positive episodes for one participant are counted as a single case.</description>
          <population>Per Protocol Population Using Per-Protocol Case Definition</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2207"/>
                <count group_id="O2" value="2305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Efficacy≥35%. Based on p≤.65/(.65+k), where p is proportion of participants with outcome in vaccine group relative to total number of participants with outcome, k is ratio of follow-up time; placebo/vaccine.
Based on conditional binomial approach.</p_value_desc>
            <method>Exact binomial test</method>
            <method_desc>Exact binomial test.</method_desc>
            <param_type>Efficacy=1-Relative Risk</param_type>
            <param_value>74.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>66.8</ci_lower_limit>
            <ci_upper_limit>79.9</ci_upper_limit>
            <estimate_desc>Efficacy = 1-RR, expressed as a percentage; the RR is the incidence in the vaccine group / the incidence in the placebo group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Hospital Admissions and Visits to Emergency Departments (or the Equivalent at International Sites) for Rotavirus Disease Associated With Serotypes G1, G2, G3, or G4</title>
        <description>Health Outcomes Substudy – Occurrence of hospital admissions and emergency department visits for episode(s) of rotavirus gastroenteritis associated with serotypes G1, G2, G3, or G4 by treatment group. Occurrence was expressed as the annual number of events per 1000 person-years.</description>
        <time_frame>At least 14 days following the 3rd vaccination</time_frame>
        <population>Per Protocol Population Using Per-Protocol Case Definition</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>Three oral doses (~6.5x10^7 to ~1.2x10^8 IU/dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Hospital Admissions and Visits to Emergency Departments (or the Equivalent at International Sites) for Rotavirus Disease Associated With Serotypes G1, G2, G3, or G4</title>
          <description>Health Outcomes Substudy – Occurrence of hospital admissions and emergency department visits for episode(s) of rotavirus gastroenteritis associated with serotypes G1, G2, G3, or G4 by treatment group. Occurrence was expressed as the annual number of events per 1000 person-years.</description>
          <population>Per Protocol Population Using Per-Protocol Case Definition</population>
          <units>Annual # of events per 1000 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28646"/>
                <count group_id="O2" value="28488"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospital admissions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emergency department visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Rate Reduction&gt;0%</p_value_desc>
            <method>Poisson regression</method>
            <method_desc>Poisson regression with generalized estimating equations.
Validated with Van Elteren’s extension of Wilcoxon Rank Sum test.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>94.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>91.2</ci_lower_limit>
            <ci_upper_limit>96.6</ci_upper_limit>
            <estimate_desc>Risk ratio of rate of hospitalizations and emergency department visits between treatment groups. Reported here are results after 12 additional emergency department visits were identified among placebo recipients and data were re-analyzed.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of a 3-dose Regimen of RotaTeq™ Against Moderate-to-severe Rotavirus Disease (Clinical Score &gt;8) Caused by Serotypes G1, G2, G3, and G4 Occurring at Least 14 Days Following the Third Dose.</title>
        <description>Number of participants with rotavirus gastroenteritis whose clinical score was &gt;8 for the first episode and for the worst episode. Scores evaluated the intensity and duration of diarrhea, vomiting, fever, and behavioral symptoms. The total score for an episode is equal to the sum of the scores for each of the symptoms [range: total score 0 (best) to 24 (worst)].</description>
        <time_frame>At least 14 days following the 3rd vaccination through the first rotavirus season</time_frame>
        <population>Per Protocol Population Using Per-Protocol Case Definition</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>Three oral doses (~6.5x10^7 to ~1.2x10^8 IU/dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of a 3-dose Regimen of RotaTeq™ Against Moderate-to-severe Rotavirus Disease (Clinical Score &gt;8) Caused by Serotypes G1, G2, G3, and G4 Occurring at Least 14 Days Following the Third Dose.</title>
          <description>Number of participants with rotavirus gastroenteritis whose clinical score was &gt;8 for the first episode and for the worst episode. Scores evaluated the intensity and duration of diarrhea, vomiting, fever, and behavioral symptoms. The total score for an episode is equal to the sum of the scores for each of the symptoms [range: total score 0 (best) to 24 (worst)].</description>
          <population>Per Protocol Population Using Per-Protocol Case Definition</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2201"/>
                <count group_id="O2" value="2292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First episode scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worst episode scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Efficacy&gt;0%. Based on p&lt; 1/(1+k), where p is proportion of participants with outcome in vaccine group relative to total number of participants with outcome, and k is ratio of follow-up time; placebo / vaccine. Based on conditional binomial approach.</p_value_desc>
            <method>Exact binomial test</method>
            <param_type>Efficacy=1-Relative Risk</param_type>
            <param_value>81.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>74.9</ci_lower_limit>
            <ci_upper_limit>86.7</ci_upper_limit>
            <estimate_desc>Estimated value is based on the worst episode scores.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of a 3-dose Regimen of RotaTeq™ Against Severe Rotavirus Disease (Clinical Score &gt; 16) Caused by Serotypes G1, G2, G3, and G4 Occurring at Least 14 Days Following the Third Dose</title>
        <description>Number of participants with rotavirus gastroenteritis whose clinical score was &gt;16 for the first episode and for the worst episode. Scores evaluated the intensity and duration of diarrhea, vomiting, fever, and behavioral symptoms. The total score for an episode is equal to the sum of the scores for each of the symptoms [range: total score 0 (best) to 24 (worst)].</description>
        <time_frame>At least 14 days following the 3rd vaccination through the first rotavirus season</time_frame>
        <population>Per Protocol Population Using Per-Protocol Case Definition</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>Three oral doses (~6.5x10^7 to ~1.2x10^8 IU/dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of a 3-dose Regimen of RotaTeq™ Against Severe Rotavirus Disease (Clinical Score &gt; 16) Caused by Serotypes G1, G2, G3, and G4 Occurring at Least 14 Days Following the Third Dose</title>
          <description>Number of participants with rotavirus gastroenteritis whose clinical score was &gt;16 for the first episode and for the worst episode. Scores evaluated the intensity and duration of diarrhea, vomiting, fever, and behavioral symptoms. The total score for an episode is equal to the sum of the scores for each of the symptoms [range: total score 0 (best) to 24 (worst)].</description>
          <population>Per Protocol Population Using Per-Protocol Case Definition</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2198"/>
                <count group_id="O2" value="2271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First episode scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worst episode scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Efficacy&gt;0%. Based on p&lt; 1/(1+k), where p is proportion of participants with outcome in vaccine group relative to total number of participants with outcome, and k is ratio of follow-up time; placebo/vaccine. Based on conditional binomial approach.</p_value_desc>
            <method>Exact binomial test</method>
            <param_type>Efficacy=1-Relative Risk</param_type>
            <param_value>98.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>88.3</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection/Seroconversion for Hepatitis B, Haemophilus Influenzae Type b, Diphtheria, Tetanus, &amp; Polio Types 1,2,&amp; 3 Who Received COMVAX™, INFANRIX™, IPOL™ &amp; PREVNAR™ Concomitantly With RotaTeq™ Versus Placebo</title>
        <description>The number of participants who achieved seroprotection/seroconversion to hepatitis B, Haemophilus influenzae type b, diphtheria, tetanus, &amp; polio types 1, 2, &amp; 3, per established criteria.</description>
        <time_frame>42 days following third dose</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>Three oral doses (~6.5x10^7 to ~1.2x10^8 IU/dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection/Seroconversion for Hepatitis B, Haemophilus Influenzae Type b, Diphtheria, Tetanus, &amp; Polio Types 1,2,&amp; 3 Who Received COMVAX™, INFANRIX™, IPOL™ &amp; PREVNAR™ Concomitantly With RotaTeq™ Versus Placebo</title>
          <description>The number of participants who achieved seroprotection/seroconversion to hepatitis B, Haemophilus influenzae type b, diphtheria, tetanus, &amp; polio types 1, 2, &amp; 3, per established criteria.</description>
          <population>Per Protocol Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="592"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hepatitis B (N=202, N=214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197"/>
                    <measurement group_id="O2" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemophilus influenzae type b (N=558, N=592)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="417"/>
                    <measurement group_id="O2" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diphtheria (N=136, N=144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus (N=132, N=140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio type 1 (N=341, N=360)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328"/>
                    <measurement group_id="O2" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio type 2 (N=341, N=359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311"/>
                    <measurement group_id="O2" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio type 3 (N=341, N=359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                    <measurement group_id="O2" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Difference (vaccine-placebo) in seroprotection rates was greater than -.10 (non-inferiority margin).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p&lt;0.001 was obtained for all comparisons. pv - pp ≥-.10, where p is proportion of participants who achieved seroprotection in the vaccine and placebo groups, respectively.</p_value_desc>
            <method>Miettenen and Nurminen</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Titer(s) (GMT) to Pertussis Toxin (PT), Pertussis Filamentous Haemagglutinin (FHA), and Pertussis Pertactin</title>
        <description>Measurement of immune response in the group that received RotaTeq™ and the group that received placebo was performed by determining geometric mean antibody titers to Pertussis Toxin (PT), Pertussis Filamentous Haemagglutinin (FHA), and Pertussis Pertactin. Antibody titers were measured with an indirect, non-competitive, enzyme immunoassay (EIA).</description>
        <time_frame>42 days following third dose</time_frame>
        <population>Per Protocol Population; excluding protocol violators and participants with invalid data based on laboratory determinations.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>Three oral doses (~6.5x10^7 to ~1.2x10^8 IU/dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titer(s) (GMT) to Pertussis Toxin (PT), Pertussis Filamentous Haemagglutinin (FHA), and Pertussis Pertactin</title>
          <description>Measurement of immune response in the group that received RotaTeq™ and the group that received placebo was performed by determining geometric mean antibody titers to Pertussis Toxin (PT), Pertussis Filamentous Haemagglutinin (FHA), and Pertussis Pertactin. Antibody titers were measured with an indirect, non-competitive, enzyme immunoassay (EIA).</description>
          <population>Per Protocol Population; excluding protocol violators and participants with invalid data based on laboratory determinations.</population>
          <units>ELISA units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis PT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.18" lower_limit="17.10" upper_limit="23.81"/>
                    <measurement group_id="O2" value="22.73" lower_limit="19.59" upper_limit="26.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis FHA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.69" lower_limit="48.01" upper_limit="64.59"/>
                    <measurement group_id="O2" value="64.33" lower_limit="55.41" upper_limit="74.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis Pertactin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.77" lower_limit="26.46" upper_limit="45.70"/>
                    <measurement group_id="O2" value="59.17" lower_limit="46.21" upper_limit="75.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The GMT Ratio between RotaTeq™ and Placebo (GMTR) for Pertussis PT was used for analysis.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>GMTR was greater than 0.5 (non-inferiority margin).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>t-test on natural log of titers</method_desc>
            <param_type>GMTR for Pertussis PT</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The GMT Ratio between RotaTeq™ and Placebo (GMTR) for Pertussis FHA was used for analysis.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>GMTR was greater than 0.5 (non-inferiority margin).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>t-test on natural log of titers</method_desc>
            <param_type>GMTR for Pertussis FHA</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The GMT Ratio between RotaTeq™ and Placebo (GMTR) for Pertussis Pertactin was used for analysis.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>GMTR was greater than 0.5 (non-inferiority margin).</non_inferiority_desc>
            <p_value>0.193</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>t-test on natural log of titers</method_desc>
            <param_type>GMTR for Pertussis Pertactin</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Titer(s) (GMT) to Pneumococcal Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F</title>
        <description>Measurement of immune response in the group that received RotaTeq™ and the group that received placebo was performed by determining geometric mean antibody titers to pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. Serum antibody titers to type-specific pneumococcal polysaccharides were determined by an EIA.</description>
        <time_frame>42 days following third dose</time_frame>
        <population>Per Protocol Population; excluding protocol violators and participants with invalid data based on laboratory determinations.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>Three oral doses (~6.5x10^7 to ~1.2x10^8 IU/dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titer(s) (GMT) to Pneumococcal Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F</title>
          <description>Measurement of immune response in the group that received RotaTeq™ and the group that received placebo was performed by determining geometric mean antibody titers to pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. Serum antibody titers to type-specific pneumococcal polysaccharides were determined by an EIA.</description>
          <population>Per Protocol Population; excluding protocol violators and participants with invalid data based on laboratory determinations.</population>
          <units>micrograms/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pneumococcal serotype 4 (N=181, N=196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="0.99" upper_limit="1.29"/>
                    <measurement group_id="O2" value="0.96" lower_limit="0.84" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumococcal serotype 6B (N=185, N=198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" lower_limit="1.93" upper_limit="2.95"/>
                    <measurement group_id="O2" value="1.72" lower_limit="1.38" upper_limit="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumococcal serotype 9V (N=166, N=181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" lower_limit="1.66" upper_limit="2.19"/>
                    <measurement group_id="O2" value="1.78" lower_limit="1.55" upper_limit="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumococcal serotype 14 (N=178, N=198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" lower_limit="3.39" upper_limit="5.29"/>
                    <measurement group_id="O2" value="4.33" lower_limit="3.55" upper_limit="5.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumococcal serotype 18C (N=166, N=180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" lower_limit="2.30" upper_limit="2.94"/>
                    <measurement group_id="O2" value="2.02" lower_limit="1.76" upper_limit="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumococcal serotype 19F (N=180, N=196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" lower_limit="1.61" upper_limit="2.42"/>
                    <measurement group_id="O2" value="1.84" lower_limit="1.55" upper_limit="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumococcal serotype 23F (N=185, N=198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="1.41" upper_limit="2.07"/>
                    <measurement group_id="O2" value="1.50" lower_limit="1.24" upper_limit="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The GMT Ratio between RotaTeq™ and Placebo (GMTR) for pneumococcal serotype 4 was used for analysis.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>GMTR was greater than 0.5 (non-inferiority margin).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>t-test on natural log of titers</method_desc>
            <param_type>GMTR for pneumococcal serotype 4</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The GMT Ratio between RotaTeq™ and Placebo (GMTR) for pneumococcal serotype 6B was used for analysis.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>GMTR was greater than 0.5 (non-inferiority margin).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>t-test on natural log of titers</method_desc>
            <param_type>GMTR for pneumococcal serotype 6B</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The GMT Ratio between RotaTeq™ and Placebo (GMTR) for pneumococcal serotype 9V was used for analysis.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>GMTR was greater than 0.5 (non-inferiority margin).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>t-test on natural log of titers</method_desc>
            <param_type>GMTR for pneumococcal serotype 9V</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The GMT Ratio between RotaTeq™ and Placebo (GMTR) for pneumococcal serotype 14 was used for analysis.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>GMTR was greater than 0.5 (non-inferiority margin).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>t-test on natural log of titers</method_desc>
            <param_type>GMTR for pneumococcal serotype 14</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The GMT Ratio between RotaTeq™ and Placebo (GMTR) for pneumococcal serotype 18C was used for analysis.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>GMTR was greater than 0.5 (non-inferiority margin).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>t-test on natural log of titers</method_desc>
            <param_type>GMTR for pneumococcal serotype 18C</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The GMT Ratio between RotaTeq™ and Placebo (GMTR) for pneumococcal serotype 19F was used for analysis.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>GMTR was greater than 0.5 (non-inferiority margin).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>t-test on natural log of titers</method_desc>
            <param_type>GMTR for pneumococcal serotype 19F</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The GMT Ratio between RotaTeq™ and Placebo (GMTR) for pneumococcal serotype 23F was used for analysis.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>GMTR was greater than 0.5 (non-inferiority margin).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>t-test on natural log of titers</method_desc>
            <param_type>GMTR for pneumococcal serotype 23F</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants in this study were followed for all serious adverse events (SAEs) and other adverse events (AEs), for up to 42 days following each study vaccination</time_frame>
      <desc>Participants listed in SAE tables (34904–RotaTeq; 34862-Placebo) are those who received study treatment. Other AEs were reported for a pre-defined subset who received ≥1 dose (4808-RotaTeq; 4796–Placebo). Although a participant may have had ≥ 2 AEs they are counted only once in a category. The same participant may appear in different categories.</desc>
      <group_list>
        <group group_id="E1">
          <title>RotaTeq™</title>
          <description>Three oral doses (~6.5x10^7 to ~1.2x10^8 IU/dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.
The Not Completed total includes participants discontinued at any time before the completion of the third study vaccination and/or the 42-day safety follow-up period post vaccination 3.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart.
The Not Completed total includes participants discontinued at any time before the completion of the third study vaccination and/or the 42-day safety follow-up period post vaccination 3.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="863" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="955" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Cerebral palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Coarctation of the aorta</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Congenital cystic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Congenital intestinal malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Cystic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Developmental glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Glycogen storage disease type ib</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Hip dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Kidney malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Polycystic liver disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pulmonary artery stenosis congenital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Retinoblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Anal skin tags</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Infantile colic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Oesophageal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Regurgitation of food</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Volvulus of bowel</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Brain death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Fever neonatal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Near sudden infant death syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Botulism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="253" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Bronchitis acute viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Campylobacter intestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Chest wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Coxsackie viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Enterovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Gastroenteritis adenovirus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Haemophilus sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Laryngotracheitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Laryngotracheo bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Meningitis enteroviral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Meningitis haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Meningitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Perianal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pneumococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pneumococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pseudocroup</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pyelocystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Roseola</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Scrotal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Tonsillitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Tuberculosis of peripheral lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Fractured skull depressed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Heat exhaustion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Injury asphyxiation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Cow's milk intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Diet refusal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Feeding disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Feeding disorder neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Hyperinsulinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Weight gain poor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chondromalacia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Growth retardation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Neuroblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pineal parenchymal neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anoxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Hypoxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Infantile spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Intraneural cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Spinal cord haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Apathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Breath holding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Staring</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Testicular torsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Apnoeic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Bronchial hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Chronic respiratory disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Neonatal apnoeic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Tracheomalacia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Eczema infantile</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Lichen sclerosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Seborrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Urticaria pigmentosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Child abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Child neglect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Overfeeding of infant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34904"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34862"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4000" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="4047" subjects_at_risk="4787"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="315" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="339" subjects_at_risk="4787"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1047" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="1022" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="273" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="282" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Infantile colic</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Regurgitation of food</sub_title>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="613" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="644" subjects_at_risk="4787"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="216" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="228" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="881" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="862" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1970" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="2056" subjects_at_risk="4787"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Candida nappy rash</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="447" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="454" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="276" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="277" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="185" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="188" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="624" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="602" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="348" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="337" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1230" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="1279" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="4787"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="4787"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="4787"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="180" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="4787"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="471" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="456" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="293" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="294" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="254" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="4787"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="4787"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="4800"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="4787"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>70,301 participants randomized, 69,274 evaluated, when DSMB first recommended ending enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

